Literature DB >> 30673042

Analysis of survival in patients with brain metastases treated surgically: Impact of age, gender, oncologic status, chemotherapy, radiotherapy, number and localization of lesions, and primary cancer site.

José Marcus Rotta1, Daniella Brito Rodrigues1, Juliete Melo Diniz1, Bianca Medeiros de Abreu1, Fernanda Kamimura1, Ulysses Oliveira Sousa1, Ricardo Vieira Botelho1, Matheus Fernandes de Oliveira1.   

Abstract

OBJECTIVE: To evaluate the survival of patients with brain metastases treated surgically according to the potentially involved factors.
METHODS: 71 patients treated surgically were analyzed with the diagnosis of brain metastases during the period from January 2011 to November 2014, totaling 47 months of follow-up. The Kaplan-Meier curve method was used for survival analysis.
RESULTS: We evaluated 71 patients with brain metastases treated surgically, 44 female and 27 male, mean age of 60.1 years. According to the Karnofsky scale, 44 patients were classified with Karnofsky greater than or equal to 70 and 27 patients with Karnofsky inferior to 70. Lung was the primary site most commonly found. Death occurred in twenty patients (28%), and lung tumors were responsible for the most deaths. Twelve patients had supra and infratentorial metastases, fifty-nine only had supratentorial lesions, and lesions were multiple in twenty-eight patients and single in forty-three. Thirty patients were also treated with chemotherapy, eighteen with chemotherapy and radiation therapy, while only three received just radiotherapy. Survival analysis by Kaplan-Meier curve showed no statistical significance regarding age, histological type, location, Karnofsky, chemotherapy, and radiotherapy. There was statistical significance regarding gender.
CONCLUSION: The factors analyzed did not change survival rates, except for gender. This fact may probably be explained due to the systemic and diffuse behavior of cancer.

Entities:  

Mesh:

Year:  2018        PMID: 30673042     DOI: 10.1590/1806-9282.64.08.717

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  6 in total

1.  Surgery for brain metastases: radiooncology scores predict survival-score index for radiosurgery, graded prognostic assessment, recursive partitioning analysis.

Authors:  Christina Wolfert; Veit Rohde; Abdelhalim Hussein; Ingo Fiss; Silvia Hernández-Durán; Dörthe Malzahn; Annalen Bleckmann; Dorothee Mielke; Bawarjan Schatlo
Journal:  Acta Neurochir (Wien)       Date:  2022-09-24       Impact factor: 2.816

2.  Brain Metastases in Elderly Patients-The Role of Surgery in the Context of Systemic Treatment.

Authors:  Martin Proescholdt; Stephanie T Jünger; Petra Schödel; Karl-Michael Schebesch; Christian Doenitz; Tobias Pukrop; Julius Höhne; Nils-Ole Schmidt; Martin Kocher; Holger Schulz; Maximilian Ruge; Kevin König; Roland Goldbrunner; Stefan Grau
Journal:  Brain Sci       Date:  2021-01-18

3.  Differentiation Between Glioblastoma Multiforme and Metastasis From the Lungs and Other Sites Using Combined Clinical/Routine MRI Radiomics.

Authors:  Yuqi Han; Lingling Zhang; Shuzi Niu; Shuguang Chen; Bo Yang; Hongyan Chen; Fei Zheng; Yuying Zang; Hongbo Zhang; Yu Xin; Xuzhu Chen
Journal:  Front Cell Dev Biol       Date:  2021-08-26

4.  Brain cryptococcoma mimicking a glioblastoma in an immunocompetent patient: A rare case report and comprehensive review.

Authors:  Anselmo Alves Boa Sorte; Cesar Carvalho Garcia; Mateus Reghin Neto; Matheus Fernandes de Oliveira; Jose Marcus Rotta
Journal:  Surg Neurol Int       Date:  2022-03-31

5.  The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting.

Authors:  Stephanie T Jünger; Lenhard Pennig; Petra Schödel; Roland Goldbrunner; Lea Friker; Martin Kocher; Martin Proescholdt; Stefan Grau
Journal:  Cancers (Basel)       Date:  2021-03-21       Impact factor: 6.639

6.  Clinical features and prognostic factors in 190 cancer patients with brain metastases.

Authors:  Min-Hang Zhou; Yuan Wu; Jun-Zhong Sun
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.